Literature DB >> 11395411

Peroxisome proliferator-activated receptor gamma and metabolic disease.

T M Willson1, M H Lambert, S A Kliewer.   

Abstract

The nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) is a transcription factor that is activated by polyunsaturated fatty acids and their metabolites and is essential for fat cell formation. Although obesity is a strong risk factor for type 2 diabetes mellitus and other metabolic diseases, potent PPAR gamma activators such as the glitazone drugs lower glucose and lipid levels in patients with type 2 diabetes and also have antiatherosclerotic and antihypertensive effects. We review recent studies providing insight into the paradoxical relationship between PPAR gamma and metabolic disease. We also review recent advances in understanding the structural basis for PPAR gamma activation by ligands. The unusual ligand-binding properties of PPAR gamma suggest that it will be possible to discover new chemical classes of receptor "modulators" with distinct pharmacological activities for the treatment of type 2 diabetes and other metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395411     DOI: 10.1146/annurev.biochem.70.1.341

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN: 0066-4154            Impact factor:   23.643


  166 in total

Review 1.  Transcriptional regulation of hepatic stellate cell activation.

Authors:  D A Mann; D E Smart
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

Review 2.  Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity.

Authors:  Thomas P Burris; Scott A Busby; Patrick R Griffin
Journal:  Chem Biol       Date:  2012-01-27

3.  Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.

Authors:  Michael L Goodson; Brenda J Mengeling; Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

4.  Peroxisome proliferator activated receptor-γ and traumatic brain injury.

Authors:  Lei Qi; Asha Jacob; Ping Wang; Rongqian Wu
Journal:  Int J Clin Exp Med       Date:  2010-09-23

5.  The effect of troglitazone on lipid accumulation and related gene expression in Hanwoo muscle satellite cell.

Authors:  You Bing Yang; Muthuraman Pandurangan; Dawoon Jeong; Inho Hwang
Journal:  J Physiol Biochem       Date:  2012-07-08       Impact factor: 4.158

Review 6.  Pioglitazone: a review of its use in type 2 diabetes mellitus.

Authors:  John Waugh; Gillian M Keating; Greg L Plosker; Stephanie Easthope; Dean M Robinson
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma.

Authors:  Serena Ghisletti; Wendy Huang; Sumito Ogawa; Gabriel Pascual; Mu-En Lin; Timothy M Willson; Michael G Rosenfeld; Christopher K Glass
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

8.  Coordinated transcriptional control of adipocyte triglyceride lipase (Atgl) by transcription factors Sp1 and peroxisome proliferator-activated receptor γ (PPARγ) during adipocyte differentiation.

Authors:  Debasish Roy; Kenneth T Farabaugh; Jing Wu; Alyssa Charrier; Cynthia Smas; Maria Hatzoglou; Kavitha Thirumurugan; David A Buchner
Journal:  J Biol Chem       Date:  2017-07-18       Impact factor: 5.157

9.  PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.

Authors:  Danielle N Lyons; Liping Zhang; Robert J Danaher; Craig S Miller; Karin N Westlund
Journal:  Clin J Pain       Date:  2017-12       Impact factor: 3.442

10.  SMRT-GPS2 corepressor pathway dysregulation coincides with obesity-linked adipocyte inflammation.

Authors:  Amine Toubal; Karine Clément; Rongrong Fan; Patricia Ancel; Veronique Pelloux; Christine Rouault; Nicolas Veyrie; Agnes Hartemann; Eckardt Treuter; Nicolas Venteclef
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.